JP2009531389A - 結合方法 - Google Patents
結合方法 Download PDFInfo
- Publication number
- JP2009531389A JP2009531389A JP2009502102A JP2009502102A JP2009531389A JP 2009531389 A JP2009531389 A JP 2009531389A JP 2009502102 A JP2009502102 A JP 2009502102A JP 2009502102 A JP2009502102 A JP 2009502102A JP 2009531389 A JP2009531389 A JP 2009531389A
- Authority
- JP
- Japan
- Prior art keywords
- pnag
- carrier protein
- activated
- linker
- protein complex
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims abstract description 75
- 102000014914 Carrier Proteins Human genes 0.000 claims abstract description 85
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 82
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 82
- 108010078791 Carrier Proteins Proteins 0.000 claims abstract description 81
- 125000003396 thiol group Chemical group [H]S* 0.000 claims abstract description 37
- 125000005439 maleimidyl group Chemical group C1(C=CC(N1*)=O)=O 0.000 claims abstract description 31
- 230000003213 activating effect Effects 0.000 claims abstract description 29
- 235000018102 proteins Nutrition 0.000 claims description 81
- 125000000217 alkyl group Chemical group 0.000 claims description 43
- 108091007433 antigens Proteins 0.000 claims description 34
- 102000036639 antigens Human genes 0.000 claims description 34
- 239000000427 antigen Substances 0.000 claims description 33
- 150000004676 glycans Chemical class 0.000 claims description 30
- 229920001282 polysaccharide Polymers 0.000 claims description 30
- 239000005017 polysaccharide Substances 0.000 claims description 30
- 229960005486 vaccine Drugs 0.000 claims description 28
- 239000012634 fragment Substances 0.000 claims description 21
- 238000011282 treatment Methods 0.000 claims description 20
- JWDFQMWEFLOOED-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(pyridin-2-yldisulfanyl)propanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCSSC1=CC=CC=N1 JWDFQMWEFLOOED-UHFFFAOYSA-N 0.000 claims description 19
- QYEAAMBIUQLHFQ-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 6-[3-(pyridin-2-yldisulfanyl)propanoylamino]hexanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCCCCNC(=O)CCSSC1=CC=CC=N1 QYEAAMBIUQLHFQ-UHFFFAOYSA-N 0.000 claims description 15
- 239000002671 adjuvant Substances 0.000 claims description 14
- 229960000814 tetanus toxoid Drugs 0.000 claims description 14
- PVGATNRYUYNBHO-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-(2,5-dioxopyrrol-1-yl)butanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCCN1C(=O)C=CC1=O PVGATNRYUYNBHO-UHFFFAOYSA-N 0.000 claims description 13
- 229910052717 sulfur Inorganic materials 0.000 claims description 13
- 125000004434 sulfur atom Chemical group 0.000 claims description 13
- 229920001542 oligosaccharide Polymers 0.000 claims description 12
- 150000002482 oligosaccharides Chemical class 0.000 claims description 12
- GKSPIZSKQWTXQG-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-[1-(pyridin-2-yldisulfanyl)ethyl]benzoate Chemical compound C=1C=C(C(=O)ON2C(CCC2=O)=O)C=CC=1C(C)SSC1=CC=CC=N1 GKSPIZSKQWTXQG-UHFFFAOYSA-N 0.000 claims description 11
- 239000002776 alpha toxin Substances 0.000 claims description 10
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 9
- 101710092462 Alpha-hemolysin Proteins 0.000 claims description 9
- 101710197219 Alpha-toxin Proteins 0.000 claims description 9
- 101710124951 Phospholipase C Proteins 0.000 claims description 9
- 125000001931 aliphatic group Chemical group 0.000 claims description 8
- 125000003118 aryl group Chemical group 0.000 claims description 8
- ULARYIUTHAWJMU-UHFFFAOYSA-M sodium;1-[4-(2,5-dioxopyrrol-1-yl)butanoyloxy]-2,5-dioxopyrrolidine-3-sulfonate Chemical compound [Na+].O=C1C(S(=O)(=O)[O-])CC(=O)N1OC(=O)CCCN1C(=O)C=CC1=O ULARYIUTHAWJMU-UHFFFAOYSA-M 0.000 claims description 8
- 125000003277 amino group Chemical group 0.000 claims description 7
- 108091008324 binding proteins Proteins 0.000 claims description 7
- 201000010099 disease Diseases 0.000 claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 6
- 102100037840 Dehydrogenase/reductase SDR family member 2, mitochondrial Human genes 0.000 claims description 5
- 101710188053 Protein D Proteins 0.000 claims description 5
- 101710132893 Resolvase Proteins 0.000 claims description 5
- 230000023555 blood coagulation Effects 0.000 claims description 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 5
- 108010071134 CRM197 (non-toxic variant of diphtheria toxin) Proteins 0.000 claims description 4
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 claims description 4
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 4
- 235000018417 cysteine Nutrition 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 4
- -1 rEPA Proteins 0.000 claims description 4
- 102220117512 rs886041928 Human genes 0.000 claims description 4
- 125000006850 spacer group Chemical group 0.000 claims description 4
- JKHVDAUOODACDU-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(2,5-dioxopyrrol-1-yl)propanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCN1C(=O)C=CC1=O JKHVDAUOODACDU-UHFFFAOYSA-N 0.000 claims description 3
- PMJWDPGOWBRILU-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-[4-(2,5-dioxopyrrol-1-yl)phenyl]butanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCCC(C=C1)=CC=C1N1C(=O)C=CC1=O PMJWDPGOWBRILU-UHFFFAOYSA-N 0.000 claims description 3
- VLARLSIGSPVYHX-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 6-(2,5-dioxopyrrol-1-yl)hexanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCCCCN1C(=O)C=CC1=O VLARLSIGSPVYHX-UHFFFAOYSA-N 0.000 claims description 3
- WCMOHMXWOOBVMZ-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 6-[3-(2,5-dioxopyrrol-1-yl)propanoylamino]hexanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCCCCNC(=O)CCN1C(=O)C=CC1=O WCMOHMXWOOBVMZ-UHFFFAOYSA-N 0.000 claims description 3
- IHVODYOQUSEYJJ-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 6-[[4-[(2,5-dioxopyrrol-1-yl)methyl]cyclohexanecarbonyl]amino]hexanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCCCCNC(=O)C(CC1)CCC1CN1C(=O)C=CC1=O IHVODYOQUSEYJJ-UHFFFAOYSA-N 0.000 claims description 3
- DIYPCWKHSODVAP-UHFFFAOYSA-N 1-[3-(2,5-dioxopyrrol-1-yl)benzoyl]oxy-2,5-dioxopyrrolidine-3-sulfonic acid Chemical compound O=C1C(S(=O)(=O)O)CC(=O)N1OC(=O)C1=CC=CC(N2C(C=CC2=O)=O)=C1 DIYPCWKHSODVAP-UHFFFAOYSA-N 0.000 claims description 3
- 101710154607 Azurocidin Proteins 0.000 claims description 3
- 102100026189 Beta-galactosidase Human genes 0.000 claims description 3
- 102100033620 Calponin-1 Human genes 0.000 claims description 3
- 101000822677 Clostridium perfringens (strain 13 / Type A) Small, acid-soluble spore protein 1 Proteins 0.000 claims description 3
- 101000822695 Clostridium perfringens (strain 13 / Type A) Small, acid-soluble spore protein C1 Proteins 0.000 claims description 3
- 108090000790 Enzymes Proteins 0.000 claims description 3
- 102000004190 Enzymes Human genes 0.000 claims description 3
- 101710141457 Histidine-binding periplasmic protein Proteins 0.000 claims description 3
- 101000945318 Homo sapiens Calponin-1 Proteins 0.000 claims description 3
- 101000652736 Homo sapiens Transgelin Proteins 0.000 claims description 3
- 102000004882 Lipase Human genes 0.000 claims description 3
- 108090001060 Lipase Proteins 0.000 claims description 3
- 239000004367 Lipase Substances 0.000 claims description 3
- CPLXHLVBOLITMK-UHFFFAOYSA-N Magnesium oxide Chemical compound [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 claims description 3
- 101710087657 Manganese ABC transporter substrate-binding lipoprotein Proteins 0.000 claims description 3
- 241000404883 Pisa Species 0.000 claims description 3
- 101710092628 Probable histidine-binding protein Proteins 0.000 claims description 3
- 101000576806 Protobothrops flavoviridis Small serum protein 1 Proteins 0.000 claims description 3
- 101000576807 Protobothrops flavoviridis Small serum protein 2 Proteins 0.000 claims description 3
- 240000005499 Sasa Species 0.000 claims description 3
- 108010031318 Vitronectin Proteins 0.000 claims description 3
- 102100035140 Vitronectin Human genes 0.000 claims description 3
- 229960003983 diphtheria toxoid Drugs 0.000 claims description 3
- 108010064033 elastin-binding proteins Proteins 0.000 claims description 3
- 235000019421 lipase Nutrition 0.000 claims description 3
- VUFNRPJNRFOTGK-UHFFFAOYSA-M sodium;1-[4-[(2,5-dioxopyrrol-1-yl)methyl]cyclohexanecarbonyl]oxy-2,5-dioxopyrrolidine-3-sulfonate Chemical compound [Na+].O=C1C(S(=O)(=O)[O-])CC(=O)N1OC(=O)C1CCC(CN2C(C=CC2=O)=O)CC1 VUFNRPJNRFOTGK-UHFFFAOYSA-M 0.000 claims description 3
- MIDXXTLMKGZDPV-UHFFFAOYSA-M sodium;1-[6-(2,5-dioxopyrrol-1-yl)hexanoyloxy]-2,5-dioxopyrrolidine-3-sulfonate Chemical compound [Na+].O=C1C(S(=O)(=O)[O-])CC(=O)N1OC(=O)CCCCCN1C(=O)C=CC1=O MIDXXTLMKGZDPV-UHFFFAOYSA-M 0.000 claims description 3
- JJAHTWIKCUJRDK-UHFFFAOYSA-N succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate Chemical compound C1CC(CN2C(C=CC2=O)=O)CCC1C(=O)ON1C(=O)CCC1=O JJAHTWIKCUJRDK-UHFFFAOYSA-N 0.000 claims description 3
- ASNTZYQMIUCEBV-UHFFFAOYSA-N 2,5-dioxo-1-[6-[3-(pyridin-2-yldisulfanyl)propanoylamino]hexanoyloxy]pyrrolidine-3-sulfonic acid Chemical compound O=C1C(S(=O)(=O)O)CC(=O)N1OC(=O)CCCCCNC(=O)CCSSC1=CC=CC=N1 ASNTZYQMIUCEBV-UHFFFAOYSA-N 0.000 claims description 2
- 241001465754 Metazoa Species 0.000 claims description 2
- NRFJZTXWLKPZAV-UHFFFAOYSA-N N-(2-oxo-3-thiolanyl)acetamide Chemical compound CC(=O)NC1CCSC1=O NRFJZTXWLKPZAV-UHFFFAOYSA-N 0.000 claims description 2
- 230000001580 bacterial effect Effects 0.000 claims description 2
- 230000000903 blocking effect Effects 0.000 claims description 2
- 229960004753 citiolone Drugs 0.000 claims description 2
- 101710128530 Fibrinogen-binding protein Proteins 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 102000025748 fibrinogen binding proteins Human genes 0.000 claims 1
- 230000001268 conjugating effect Effects 0.000 abstract 1
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 24
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 16
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 13
- 241000191963 Staphylococcus epidermidis Species 0.000 description 13
- 239000000203 mixture Substances 0.000 description 12
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 11
- 239000002953 phosphate buffered saline Substances 0.000 description 11
- 150000001413 amino acids Chemical group 0.000 description 10
- 208000015181 infectious disease Diseases 0.000 description 10
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 9
- 238000010828 elution Methods 0.000 description 9
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 8
- 241000191967 Staphylococcus aureus Species 0.000 description 8
- 230000028993 immune response Effects 0.000 description 7
- 230000002163 immunogen Effects 0.000 description 7
- 239000012528 membrane Substances 0.000 description 7
- 239000011780 sodium chloride Substances 0.000 description 7
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
- 239000012506 Sephacryl® Substances 0.000 description 6
- 235000001014 amino acid Nutrition 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 108020001507 fusion proteins Proteins 0.000 description 6
- 102000037865 fusion proteins Human genes 0.000 description 6
- 229940035032 monophosphoryl lipid a Drugs 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 241000295644 Staphylococcaceae Species 0.000 description 5
- 229930182558 Sterol Natural products 0.000 description 5
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 5
- 238000005859 coupling reaction Methods 0.000 description 5
- 150000002632 lipids Chemical class 0.000 description 5
- 239000002502 liposome Substances 0.000 description 5
- 150000003432 sterols Chemical class 0.000 description 5
- 235000003702 sterols Nutrition 0.000 description 5
- 108090000695 Cytokines Proteins 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 210000001744 T-lymphocyte Anatomy 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 230000008878 coupling Effects 0.000 description 4
- 238000010168 coupling process Methods 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 244000052769 pathogen Species 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 108010077805 Bacterial Proteins Proteins 0.000 description 3
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 3
- 206010041925 Staphylococcal infections Diseases 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000004132 cross linking Methods 0.000 description 3
- 238000011033 desalting Methods 0.000 description 3
- PGLTVOMIXTUURA-UHFFFAOYSA-N iodoacetamide Chemical compound NC(=O)CI PGLTVOMIXTUURA-UHFFFAOYSA-N 0.000 description 3
- 239000007764 o/w emulsion Substances 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 102000005416 ATP-Binding Cassette Transporters Human genes 0.000 description 2
- 108010006533 ATP-Binding Cassette Transporters Proteins 0.000 description 2
- 0 C*C(*=C(C)NNC)=O Chemical compound C*C(*=C(C)NNC)=O 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 2
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 2
- 241000606768 Haemophilus influenzae Species 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 2
- 206010029803 Nosocomial infection Diseases 0.000 description 2
- 108700022034 Opsonin Proteins Proteins 0.000 description 2
- 206010035664 Pneumonia Diseases 0.000 description 2
- 206010043376 Tetanus Diseases 0.000 description 2
- 108010059993 Vancomycin Proteins 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 2
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000021615 conjugation Effects 0.000 description 2
- 239000003431 cross linking reagent Substances 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 238000002523 gelfiltration Methods 0.000 description 2
- 239000005090 green fluorescent protein Substances 0.000 description 2
- 229940047650 haemophilus influenzae Drugs 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 239000000411 inducer Substances 0.000 description 2
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229960003085 meticillin Drugs 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- WHMDPDGBKYUEMW-UHFFFAOYSA-N pyridine-2-thiol Chemical compound SC1=CC=CC=N1 WHMDPDGBKYUEMW-UHFFFAOYSA-N 0.000 description 2
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 229930182490 saponin Natural products 0.000 description 2
- 150000007949 saponins Chemical class 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 description 2
- 238000000527 sonication Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 229960001295 tocopherol Drugs 0.000 description 2
- 229930003799 tocopherol Natural products 0.000 description 2
- 235000010384 tocopherol Nutrition 0.000 description 2
- 239000011732 tocopherol Substances 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 108700012359 toxins Proteins 0.000 description 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
- 208000019206 urinary tract infection Diseases 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- 229960003165 vancomycin Drugs 0.000 description 2
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 2
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 2
- 230000001018 virulence Effects 0.000 description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- SNKAWJBJQDLSFF-NVKMUCNASA-N 1,2-dioleoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC SNKAWJBJQDLSFF-NVKMUCNASA-N 0.000 description 1
- LCZVQHWMSQLWSC-UHFFFAOYSA-N 1-[4-(2,5-dioxopyrrol-1-yl)butanoyloxy]-2,5-dioxopyrrolidine-3-sulfonic acid Chemical compound O=C1C(S(=O)(=O)O)CC(=O)N1OC(=O)CCCN1C(=O)C=CC1=O LCZVQHWMSQLWSC-UHFFFAOYSA-N 0.000 description 1
- IJFVSSZAOYLHEE-UHFFFAOYSA-N 2,3-di(dodecanoyloxy)propyl 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCC(=O)OCC(COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCC IJFVSSZAOYLHEE-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010053555 Arthritis bacterial Diseases 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 238000009010 Bradford assay Methods 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 208000037041 Community-Acquired Infections Diseases 0.000 description 1
- 206010011409 Cross infection Diseases 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 108010084884 GDP-mannose transporter Proteins 0.000 description 1
- 102000005720 Glutathione transferase Human genes 0.000 description 1
- 108010070675 Glutathione transferase Proteins 0.000 description 1
- 101001015673 Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd) Glycerophosphodiester phosphodiesterase Proteins 0.000 description 1
- 101710154606 Hemagglutinin Proteins 0.000 description 1
- 208000004575 Infectious Arthritis Diseases 0.000 description 1
- 108090000174 Interleukin-10 Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 102000004388 Interleukin-4 Human genes 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 102000002297 Laminin Receptors Human genes 0.000 description 1
- 108010000851 Laminin Receptors Proteins 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 206010031252 Osteomyelitis Diseases 0.000 description 1
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 1
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 101710183389 Pneumolysin Proteins 0.000 description 1
- 101710176177 Protein A56 Proteins 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 108091030066 RNAIII Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 208000031650 Surgical Wound Infection Diseases 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 206010044248 Toxic shock syndrome Diseases 0.000 description 1
- 231100000650 Toxic shock syndrome Toxicity 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 125000003172 aldehyde group Chemical group 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229940024545 aluminum hydroxide Drugs 0.000 description 1
- 229940024546 aluminum hydroxide gel Drugs 0.000 description 1
- SMYKVLBUSSNXMV-UHFFFAOYSA-K aluminum;trihydroxide;hydrate Chemical compound O.[OH-].[OH-].[OH-].[Al+3] SMYKVLBUSSNXMV-UHFFFAOYSA-K 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 238000011203 antimicrobial therapy Methods 0.000 description 1
- 239000003637 basic solution Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 208000037815 bloodstream infection Diseases 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 108010055222 clotting enzyme Proteins 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 235000013345 egg yolk Nutrition 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000012149 elution buffer Substances 0.000 description 1
- 206010014665 endocarditis Diseases 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 239000000185 hemagglutinin Substances 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000002480 immunoprotective effect Effects 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 244000039328 opportunistic pathogen Species 0.000 description 1
- 230000000399 orthopedic effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 229920002704 polyhistidine Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000000601 reactogenic effect Effects 0.000 description 1
- 238000006268 reductive amination reaction Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 201000001223 septic arthritis Diseases 0.000 description 1
- 238000004513 sizing Methods 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000006177 thiolation reaction Methods 0.000 description 1
- 229960001005 tuberculin Drugs 0.000 description 1
- 125000001493 tyrosinyl group Chemical class [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 229940124856 vaccine component Drugs 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/085—Staphylococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55544—Bacterial toxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/831—Drug, bio-affecting and body treating compositions involving capsular polysaccharide of bacterium, e.g. polyribosyl ribitol phosphate
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Toxicology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
(a)マレイミド基を含むリンカーを添加することによりPNAGを活性化して、活性化PNAGを生成するステップ;
(b)スルフィドリル基を含むリンカーを添加することによりキャリアタンパク質を活性化して、活性化キャリアタンパク質を生成するステップ;及び
(c)上記活性化PNAGと上記活性化キャリアタンパク質とを反応させて、PNAG−キャリアタンパク質複合体を生成するステップ;
を含む、あるいは
(a)スルフィドリル基を含むリンカーを添加することによりPNAGを活性化して、活性化PNAGを生成するステップ;
(b)マレイミド基を含むリンカーを添加することによりキャリアタンパク質を活性化して、活性化キャリアタンパク質を生成するステップ;及び
(c)上記活性化PNAGと上記活性化キャリアタンパク質とを反応させて、PNAG−キャリアタンパク質複合体を生成するステップ;
を含む、あるいは
(a)スルフィドリル基を含むリンカーを添加することによりPNAGを活性化して、活性化PNAGを生成するステップ;
(b)スルフィドリル基を含むリンカーを添加することによりキャリアタンパク質を活性化して、活性化キャリアタンパク質を生成するステップ;及び
(c)上記活性化PNAGと上記活性化キャリアタンパク質とを反応させて、PNAG−キャリアタンパク質複合体を生成するステップ
を含む方法を提供する。
(a)マレイミド基を含むリンカーを添加することによりPNAGを活性化して、活性化PNAGを生成するステップ;
(b)スルフィドリル基を含むリンカーを添加することによりキャリアタンパク質を活性化して、活性化キャリアタンパク質を生成するステップ;及び
(c)上記活性化PNAGと上記活性化キャリアタンパク質とを反応させて、PNAG−キャリアタンパク質複合体を生成するステップ
を含む方法を記載する。
(a)マレイミド基を含むリンカーを添加することによりキャリアタンパク質を活性化して、活性化キャリアタンパク質を生成するステップ;
(b)スルフィドリル基を含むリンカーを添加することによりPNAGを活性化して、活性化PNAGを生成するステップ;及び
(c)上記活性化PNAGと上記活性化キャリアタンパク質とを反応させて、PNAG−キャリアタンパク質複合体を生成するステップ;
を含む方法を記載する。
(a)スルフィドリル基を含むリンカーを添加することによりキャリアタンパク質を活性化して、活性化キャリアタンパク質を生成するステップ;
(b)スルフィドリル基を含むリンカーを添加することによりPNAGを活性化して、活性化PNAGを生成するステップ;及び
(c)上記活性化PNAGと上記活性化キャリアタンパク質とを反応させて、PNAG−キャリアタンパク質複合体を生成するステップ
を含む方法を記載する。
5型
→4)-β-D-ManNAcA-(1→4)-α-L-FucNAc(3OAc)-(1→3)-β-D-FucNAc-(1→
8型
→3)-β-D-ManNAcA(4OAc)-(1→3)-α-L-FucNAc(1→3)-α-D-FucNAc(1→
dPNAGをWO04/43405号に記載のように調製した。dPNAGをさらにSuperose6カラムで精製した。
dPNAG(12mg)を、300μlの5M HCl+300μlの5M NaOH+1700μlの1×PBS(pH7.0)に溶解し、pH7.0に調整した。サンプルを0.22μmフィルターを通してろ過し、再度pHを7.0に調整した。12mgのGMBSを200μlのDMSOに溶解し、サンプルを暗所で室温にて2時間ゆっくりと攪拌した。0.5M NaOHを用いてpHを7.0に維持した。1×PBS、10mM EDTA(pH7.0)バッファーで平衡化した脱塩カラム(PD10カラム)を用いて過剰のGMBSを除き、Centricon10KDa MWCO濃縮デバイスを用いてサンプルを0.6mlになるまで濃縮した。
破傷風トキソイド(TT)(6.5mg;195μl原液)を1105μlの1×PBS含有10mM EDTA(pH8.0)に添加した。130μlのSPDP(DMSO中6.2mg/ml)をタンパク質溶液に添加し、暗所で室温にて1時間ゆっくりと攪拌した。0.5M NaOHを用いてpHを8.0に維持した。1×PBS、10mM EDTA(pH8.0)バッファーで平衡化した脱塩カラム(PD10カラム)を用いて過剰のSPDPを除き、Centricon10KDa MWCOを用いてサンプルを1.3mlになるまで濃縮した。0.65mlのDTT(1×PBS、10mM EDTA(pH8.0)バッファー中23mg/ml)を1.3mlのSPDP活性化TTに添加した。サンプルを暗所で室温にて30分間インキュベートした。0.5M NaOHを用いてpHを8.0に維持した。1×PBS、10mM EDTA(pH7.0)バッファーで平衡化した脱塩カラム(PD10カラム)を用いて過剰のDTTを除き、Centricon10KDa MWCO濃縮デバイスを用いてサンプルを0.6mlになるまで濃縮した。
dPNAG:153.37μg/ml (46.3%)
TT: 178.06μg/ml (53.7%)
dPNAG−TT複合体
本明細書の以下に記載する手法を用いて、下記の複合体を生成した:
dPNAG−TT010:dPNAG−S−GMBS+DTT処理TT−LC−SPDP
dPNAG−TT011:dPNAG−S−GMBS+DTT処理TT−LC−SPDP
dPNAG−TT012:dPNAG−S−GMBS+DTT処理TT−SPDP
dPNAG−TT014:dPNAG−SPDP+DTT処理TT−SPDP
dPNAG−TT017:DTT処理dPNAG−SPDP+TT−LC−SPDP
dPNAG−TT019:dPNAG−S−GMBS+DTT処理TT−SPDP
dPNAG−TT020:dPNAG−S−GMBS+DTT処理TT−SPDP
1gのPNAGを20mg/mlの濃度で5N HClに溶解し、1時間インキュベートした。続いて5N NaOHを用いて中和した。この溶液を5μm膜において清澄化し、Sephacryl S400HRにおいて精製した。目的の画分、すなわち「中間の分子サイズ」(Infection and Immunity, 70: 4433-4440 (2002)を参照)に相当するものをプールし、濃縮したあと、脱N−アセチル化処理を行った。
S−GMBS(N−(γ−マレイミドブチリルオキシ)スルホスクシンイミド、Pierce)を0.2M NaCl中のdPNAGに添加し(比S−GMBS/PS(w/w):1/1)、pH7.0(1M NaOHを用いてpH調節)にて室温で2時間にわたりインキュベートした。ToyopearlHW−40FにおいてPBS、10mM EDTA、50mM NaCl(pH7.2)を溶出バッファーとして60ml/時の一定の流速で用いて精製することにより過剰のGMBSと副産物を除去した。溶出プールを光学密度(UV=206nm)の関数で選択し、続いてVivaspin管3,000MWCO又はAmiconUltra 10,000MWCOにおいて濃縮した。
GMBS活性化dPNAG及びDTT還元(reduced)TT−SPDPを混合し、室温で攪拌した。使用した条件に応じて、システイン(リン酸ナトリウムバッファーpH8.0中4mg/ml)を30分かけて添加することにより20〜120分後に反応を停止させた。複合体を5μmフィルターを用いて清澄化し、精製のためにSephacryl S300HR樹脂(XK16/100)に注入した。200mM NaClを用いて30ml/時の一定の流速で溶出を行った。溶出画分をヘキソサミンにより及びタンパク質用量により分析した。目的の画分をプールし、0.22μm Sterivexにおいてろ過した。最終的な複合体は、多糖(ヘキソサミン用量)及びタンパク質組成(ローリー用量)について試験した。
DMSO(ジメチルスルホキシド,Merck)に溶解した5倍モル過剰のSPDP(N−スクシンイミジル−3−(2−ピリジルジチオ)プロピオネート,MW:312.4,Pierce)を、100mMリン酸ナトリウム(pH7.2)中5mg/mlのdPNAG100mgに添加し、室温で1時間インキュベートした。反応混合物をAmiconUltra 10,000MWCO(3000rpmで28分間の遠心)で±6mlにまで濃縮した後、Sephacryl S100HR(XK16/40)で精製を行った。リン酸バッファー(pH7.4)を用いて60ml/時の一定の流速で溶出を行った。目的の画分(206nmで読み取り)をプールし、AmiconUltra 10,000MWCO(3000rpmで30分間の遠心)において1.1mlになるまで濃縮した。
DMSO(ジメチルスルホキシド,Merck)に溶解した15倍モル過剰のSPDP(Pierce)を、100mMリン酸ナトリウム(pH7.2)中のTT(50/ml)1gに添加し、室温で80分間インキュベートした。続いて、生成物をSephacryl S100HR(XK16/40)に注入し、100mM酢酸ナトリウム(pH5.6),100mM NaCl,1mM EDTAを60ml/時の一定の流速で用いて溶出した。溶出プールを光学密度(UV=280nm)の関数で選択し、続いてAmiconUltra 10,000MWCO(3000rpmで75分間の遠心)において19.6mlになるまで濃縮した。
DTTをTT−SPDP又はTT−LC−SPDPにDTT/TT比(mg/mg)が0.7/1となるよう添加した。室温で2時間後、ピリジン−2−チオンが放出されて、その特徴的な吸収が343nmとなった。ゲルろ過(PD−10,Amersham)によりチオール化タンパク質を過剰のDTTから精製した。AmiconUltra 10,000MWCOにおいて濃縮した後、タンパク質含量をローリー用量により評価した。
カップリングは、連続的に攪拌しながら、初期TT/PS比(w/w)2/1で、室温にて実施した。
11.6mgのDTT(1,4−ジチオトレイトール,Boerhinger Mannheim,MW:154.24)を16.5mgのdPNAG−SPDPに添加した。室温で2時間後、ピリジン−2−チオンが放出されて、その特徴的な吸収が343nmとなった。ゲルろ過(Toyopearl HW40F)によりチオール化PSを過剰のDTTから精製し、続いてAmiconUltra 10,000MWCOにおいて860μlになるまで濃縮した。
カップリングは、連続的に攪拌しながら、初期TT/PS比(w/w)1.7/1で、室温にて実施した。
30匹のマウスの群に、黄色ブドウ球菌dPNAG−TT複合体(糖用量0.3μg)をアジュバント無添加で又は3D−MPLアジュバントと組み合わせて皮下接種した。マウスには、0日、14日及び28日目に3回の接種を行った。41日目にマウスから血清を採取し、各血清サンプルをELISAで試験して、PNAGに対する免疫応答を評価した。10匹のマウスの群を対照群として使用し、生理食塩水を接種した。
精製PNAG(2.5μg/ml)をリン酸緩衝生理食塩水(PBS)で希釈したメチル化HSA(2.5μg/ml)と混合し、高結合マイクロタイタープレート(Nunc Maxisorp)に4℃で一晩かけてコーティングした。
Claims (45)
- 40%未満がN−アセチル化されているPNAGとキャリアタンパク質とを結合する方法であって、
(a)マレイミド基を含むリンカーを添加することによりPNAGを活性化して、活性化PNAGを生成するステップ;
(b)スルフィドリル基を含むリンカーを添加することによりキャリアタンパク質を活性化して、活性化キャリアタンパク質を生成するステップ;及び
(c)上記活性化PNAGと上記活性化キャリアタンパク質とを反応させて、PNAG−キャリアタンパク質複合体を生成するステップ
を含む方法。 - 40%未満がN−アセチル化されているPNAGとキャリアタンパク質とを結合する方法であって、
(a)スルフィドリル基を含むリンカーを添加することによりPNAGを活性化して、活性化PNAGを生成するステップ;
(b)マレイミド基を含むリンカーを添加することによりキャリアタンパク質を活性化して、活性化キャリアタンパク質を生成するステップ;及び
(c)上記活性化PNAGと上記活性化キャリアタンパク質とを反応させて、PNAG−キャリアタンパク質複合体を生成するステップ
を含む方法。 - 40%未満がN−アセチル化されているPNAGとキャリアタンパク質とを結合する方法であって、
(a)スルフィドリル基を含むリンカーを添加することによりPNAGを活性化して、活性化PNAGを生成するステップ;
(b)スルフィドリル基を含むリンカーを添加することによりキャリアタンパク質を活性化して、活性化キャリアタンパク質を生成するステップ;及び
(c)上記活性化PNAGと上記活性化キャリアタンパク質とを反応させて、PNAG−キャリアタンパク質複合体を生成するステップ
を含む方法。 - マレイミド基を含むリンカーが、ステップ(a)においてPNAGのアミン基に付加される、請求項1記載の方法。
- マレイミド基を含むリンカーが、ステップ(b)においてキャリアタンパク質のアミン基に付加される、請求項2記載の方法。
- マレイミド基を含むリンカーが、BMPS、EMCS、GMBS、MBS、LC−SMCC、SMCC、SMPB、SMPH、スルホ−EMCS、スルホ−MBS、スルホ−SMCC、スルホ−GMBS及びスルホ−SMPBからなる群より選択される、請求項1〜2又は4〜5記載の方法。
- マレイミド基を含むリンカーが、GMBS又はスルホ−GMBSである、請求項6記載の方法。
- ステップ(a)において、PNAGとマレイミド基を含むリンカーの重量/重量比が1:2〜2:1である、請求項1〜7のいずれか1項に記載の方法。
- マレイミド基を含むリンカーを添加することにより活性化するステップが、pH6.0〜8.0で行われる、請求項1〜8のいずれか1項に記載の方法。
- スルフィドリル基を含むリンカーが、ステップ(b)においてキャリアタンパク質のアミン基に付加される、請求項1、3、4又は6〜9のいずれか1項に記載の方法。
- スルフィドリル基を含むリンカーが、SPDP、LC−SPDP、SMPT、LC−SMPT、スルホ−SPDP、スルホ−SMPT、スルホ−LC−SMPT、スルホ−LC−SPDP及びN−アセチルホモシステインチオラクトンからなる群より選択される、請求項1〜10のいずれか1項に記載の方法。
- スルフィドリル基を含むリンカーが、SPDP又はLC−SPDPである、請求項11記載の方法。
- スルフィドリル基を含むリンカーが、5〜10オングストロームのスペーサー長を有する、請求項11記載の方法。
- スルフィドリル基を含むリンカーが、10〜25又は15〜20オングストロームのスペーサー長を有する、請求項11記載の方法。
- スルフィドリル基を含むリンカーを添加することにより活性化するステップにおいて、キャリアタンパク質又はPNAGとスルフィドリル基を含むリンカーの重量/重量比が50:1〜2:1である、請求項1〜14のいずれか1項に記載の方法。
- スルフィドリル基を含むリンカーを添加することにより活性化するステップが、pH7.0〜9.0で行われる、請求項1〜15のいずれか1項に記載の方法。
- ステップ(c)において、活性化PNAGと活性化キャリアタンパク質の重量/重量比が4:1〜1:4である、請求項1〜16のいずれか1項に記載の方法。
- ステップ(c)が、pH6.0〜9.0で行われる、請求項1〜17のいずれか1項に記載の方法。
- 過剰の活性化基をシステインでブロッキングするさらなるステップ(d)を含む、請求項1〜18のいずれか1項に記載の方法。
- キャリアタンパク質が、破傷風トキソイド、ジフテリアトキソイド、CRM197、rEPA、プロテインD、SitC/MntC/唾液結合タンパク質、EbhA、EbhB、エラスチン結合タンパク質(EbpS)、EFB(FIB)、SBI、ClfA、SdrC、SdrG、SdrH、リパーゼGehD、SasA、FnbA、FnbB、Cna、ClfB、FbpA、Npase、IsaA/PisA、SsaA、EPB、SSP−1、SSP−2、HBP、ビトロネクチン結合タンパク質、フィブリノーゲン結合タンパク質、血液凝固酵素、Fig、MAP、IsdA、IsdB、HarA、SitC、αトキシン(Hla)、αトキシンH35R変異体、MRPII及びオートリシン、又はこれらの断片からなる群より選択される、請求項1〜19のいずれか1項に記載の方法。
- 請求項1〜20のいずれか1項に記載の方法を実施するステップ、及びPNAG−キャリアタンパク質複合体と薬学的に許容される賦形剤とを混合するさらなるステップを含む、ワクチンの製造方法。
- PNAG−キャリアタンパク質複合体とさらなる抗原(複数でもよい)とを混合するさらなるステップを含む、請求項21記載の方法。
- さらなる抗原(複数でもよい)が、細菌多糖又はオリゴ糖を含む、請求項22記載の方法。
- さらなる抗原が、5型及び/又は8型黄色ブドウ球菌由来の莢膜多糖又はオリゴ糖を含む、請求項23記載の方法。
- さらなる抗原(複数でもよい)が、黄色ブドウ球菌由来の336抗原を含む、請求項22又は23記載の方法。
- さらなる抗原(複数でもよい)が、ブドウ球菌タンパク質又はその断片を含む、請求項22〜26のいずれか1項に記載の方法。
- ブドウ球菌タンパク質又はその断片が、WO06/32475号の図1に示される配列のいずれか1つに対して少なくとも80%の同一性を有するアミノ酸配列を含む、請求項26記載の方法。
- PNAG−キャリアタンパク質複合体がアジュバントと混合される、請求項21〜27のいずれか1項に記載の方法。
- 請求項1〜20のいずれか1項に記載の方法により得られるPNAG−キャリアタンパク質複合体。
- PNAGの40%未満がN−アセチル化されており、PNAGとキャリアタンパク質が、硫黄原子に結合したマレイミド基を含むリンカーにより結合している、PNAG−キャリアタンパク質複合体。
- マレイミド基がPNAGと硫黄原子の間に位置している、請求項30記載のPNAG−キャリアタンパク質複合体。
- マレイミド基がキャリアタンパク質と硫黄原子の間に位置している、請求項30記載のPNAG−キャリアタンパク質複合体。
- PNAGの40%未満がN−アセチル化されており、PNAGとキャリアタンパク質が、硫黄原子に結合した硫黄原子を含むリンカーにより結合している、PNAG−キャリアタンパク質複合体。
- R1がC1−C6アルキルである、請求項33、34又は36記載のPNAG−キャリアタンパク質複合体。
- R2がC1−C6アルキルである、請求項33、34、36又は37記載のPNAG−キャリアタンパク質複合体。
- マレイミド基を含むリンカーと共有結合している、40%未満がN−アセチル化されている活性化PNAG。
- 請求項29〜39のいずれか1項に記載のPNAG−キャリアタンパク質複合体及び薬学的に許容される賦形剤を含むワクチン。
- ブドウ球菌疾患の治療又は予防に使用するための、請求項29〜39のいずれか1項に記載のPNAG−キャリアタンパク質複合体。
- ブドウ球菌疾患の治療又は予防のためのワクチンの製造における、請求項29〜39のいずれか1項に記載のPNAG−キャリアタンパク質複合体の使用。
- 請求項42記載のワクチンをヒト又は動物患者に投与するステップを含む、ブドウ球菌疾患の治療又は予防方法。
Applications Claiming Priority (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US78724906P | 2006-03-30 | 2006-03-30 | |
US78758706P | 2006-03-30 | 2006-03-30 | |
GB0606417.4 | 2006-03-30 | ||
US60/787,587 | 2006-03-30 | ||
US60/787,249 | 2006-03-30 | ||
GB0606417A GB0606417D0 (en) | 2006-03-30 | 2006-03-30 | Immunogenic composition |
GB0606416A GB0606416D0 (en) | 2006-03-30 | 2006-03-30 | Immunogenic composition |
GB0606416.6 | 2006-03-30 | ||
PCT/EP2007/053060 WO2007113224A2 (en) | 2006-03-30 | 2007-03-29 | Conjugation process for pnag and a carrier protein |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2009531389A true JP2009531389A (ja) | 2009-09-03 |
JP5759671B2 JP5759671B2 (ja) | 2015-08-05 |
Family
ID=38180026
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009502101A Active JP5491853B2 (ja) | 2006-03-30 | 2007-03-29 | 免疫原性組成物 |
JP2009502102A Active JP5759671B2 (ja) | 2006-03-30 | 2007-03-29 | 結合方法 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009502101A Active JP5491853B2 (ja) | 2006-03-30 | 2007-03-29 | 免疫原性組成物 |
Country Status (8)
Country | Link |
---|---|
US (2) | US8933218B2 (ja) |
EP (2) | EP2026841B1 (ja) |
JP (2) | JP5491853B2 (ja) |
AR (2) | AR060188A1 (ja) |
CA (2) | CA2647450C (ja) |
ES (2) | ES2659050T3 (ja) |
TW (1) | TWI425951B (ja) |
WO (2) | WO2007113223A2 (ja) |
Families Citing this family (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2501077C (en) | 2002-11-12 | 2016-06-21 | Gerald B. Pier | Polysaccharide vaccine for staphylococcal infections |
AU2005236068C1 (en) | 2004-04-21 | 2012-08-30 | Beth Israel Deaconess Medical Center, Inc. | Poly-N-acetyl glucosamine (PNAG/DPNAG)-binding peptides and methods of use thereof |
KR101408113B1 (ko) | 2005-06-27 | 2014-06-16 | 글락소스미스클라인 바이오로지칼즈 에스.에이. | 백신 제조 방법 |
AR060188A1 (es) * | 2006-03-30 | 2008-05-28 | Glaxosmithkline Biolog Sa | Procedimiento de conjugacion |
US8146781B2 (en) * | 2007-08-09 | 2012-04-03 | Huhtamaki, Inc. | Dispenser for viscous condiments |
US9181329B2 (en) | 2007-08-31 | 2015-11-10 | The University Of Chicago | Methods and compositions related to immunizing against Staphylococcal lung diseases and conditions |
CA2697538C (en) | 2007-08-31 | 2019-02-12 | University Of Chicago | Methods and compositions related to immunizing against staphylococcal lung diseases and conditions |
US8466167B2 (en) | 2008-03-03 | 2013-06-18 | Irm Llc | Compounds and compositions as TLR activity modulators |
RU2532911C2 (ru) * | 2008-07-21 | 2014-11-20 | Дзе Брихэм Энд Уимен'З Хоспитал, Инк. | Способы и композиции, относящиеся к синтетическим бета-1,6-глюкозаминолигосахаридам |
WO2010014304A1 (en) | 2008-07-29 | 2010-02-04 | University Of Chicago | Compositions and methods related to staphylococcal bacterium proteins |
KR20170102039A (ko) | 2009-04-03 | 2017-09-06 | 유니버시티 오브 시카고 | 단백질 A(SpA) 변이체와 관련된 조성물 및 방법 |
PL2510947T3 (pl) * | 2009-04-14 | 2016-09-30 | Kompozycje do immunizacji przeciwko Staphylococcus aureus | |
TR201802380T4 (tr) | 2009-06-10 | 2018-03-21 | Glaxosmithkline Biologicals Sa | Benzonaftiridin içeren aşılar. |
WO2010151544A1 (en) * | 2009-06-22 | 2010-12-29 | Wyeth Llc | Immunogenic compositions of staphylococcus aureus antigens |
JP2012530785A (ja) * | 2009-06-22 | 2012-12-06 | ワイス・エルエルシー | 組成物および黄色ブドウ球菌(Staphylococcusaureus)血清型5および8莢膜多糖コンジュゲート免疫原性組成物を調製するための方法 |
TWI445708B (zh) | 2009-09-02 | 2014-07-21 | Irm Llc | 作為tlr活性調節劑之化合物及組合物 |
AU2010290896B2 (en) | 2009-09-02 | 2014-07-03 | Glaxosmithkline Biologicals S.A. | Immunogenic compositions including TLR activity modulators |
CA2779798C (en) | 2009-09-30 | 2019-03-19 | Novartis Ag | Conjugation of staphylococcus aureus type 5 and type 8 capsular polysaccharides |
JP5914344B2 (ja) | 2009-10-30 | 2016-05-11 | ノバルティス アーゲー | Staphylococcusaureus5型および8型の莢膜糖の精製 |
WO2011057148A1 (en) | 2009-11-05 | 2011-05-12 | Irm Llc | Compounds and compositions as tlr-7 activity modulators |
GB0919690D0 (en) | 2009-11-10 | 2009-12-23 | Guy S And St Thomas S Nhs Foun | compositions for immunising against staphylococcus aureus |
JP5814933B2 (ja) | 2009-12-15 | 2015-11-17 | ノバルティス アーゲー | 免疫増強化合物の均質な懸濁物およびその使用 |
EP2549990A1 (en) | 2010-03-23 | 2013-01-30 | Irm Llc | Compounds (cystein based lipopeptides) and compositions as tlr2 agonists used for treating infections, inflammations, respiratory diseases etc. |
US8808699B2 (en) | 2010-04-05 | 2014-08-19 | The University Of Chicago | Compositions and methods related to protein A (SpA) antibodies as an enhancer of immune response |
EP2560981A2 (en) * | 2010-04-23 | 2013-02-27 | Ancora Pharmaceuticals Inc. | Synthetic oligosaccharides for staphylococcus vaccine |
EP2942061A3 (en) * | 2010-06-07 | 2016-01-13 | Pfizer Vaccines LLC | Ige ch3 peptide vaccine |
AU2011274367B2 (en) | 2010-07-02 | 2015-04-23 | The University Of Chicago | Compositions and methods related to protein A (SpA) variants |
US9192661B2 (en) | 2010-07-06 | 2015-11-24 | Novartis Ag | Delivery of self-replicating RNA using biodegradable polymer particles |
WO2012034067A1 (en) | 2010-09-09 | 2012-03-15 | The University Of Chicago | Methods and compositions involving protective staphylococcal antigens |
DK3150222T3 (da) * | 2010-12-22 | 2020-01-27 | Wyeth Llc | Stabile immunogene sammensætninger af staphylococcus aureus-antigener |
WO2012170097A2 (en) * | 2011-03-16 | 2012-12-13 | Regents Of The University Of Minnesota | Compositions and methods for inducing immune responses against bacteria in the genus staphylococcus |
US9085631B2 (en) * | 2011-04-08 | 2015-07-21 | Nov Vac APS | Proteins and nucleic acids useful in vaccines targeting Staphylococcus aureus |
US8945588B2 (en) | 2011-05-06 | 2015-02-03 | The University Of Chicago | Methods and compositions involving protective staphylococcal antigens, such as EBH polypeptides |
CA2845259A1 (en) | 2011-08-15 | 2013-02-21 | The University Of Chicago | Compositions and methods related to antibodies to staphylococcal protein a |
JP6251730B2 (ja) | 2012-04-26 | 2017-12-20 | ザ・ユニバーシティ・オブ・シカゴThe University Of Chicago | 黄色ブドウ球菌(staphylococcusaureus)疾患の間にコアグラーゼ活性を中和する抗体に関連した組成物および方法 |
NZ702285A (en) | 2012-04-26 | 2016-07-29 | Univ Chicago | Staphylococcal coagulase antigens and methods of their use |
CN105188747A (zh) | 2013-02-01 | 2015-12-23 | 葛兰素史密斯克莱生物公司 | 包含toll样受体激动剂的免疫组合物的皮内递送 |
GB201310008D0 (en) * | 2013-06-05 | 2013-07-17 | Glaxosmithkline Biolog Sa | Immunogenic composition for use in therapy |
CA2932225C (en) | 2013-12-04 | 2023-01-17 | Glycovaxyn Ag | Prevention of staphylococcus aureus infections by glycoprotein vaccines synthesized in escherichia coli |
EP3229833A1 (en) * | 2014-12-10 | 2017-10-18 | GlaxoSmithKline Biologicals SA | Method of treatment |
US11214600B2 (en) * | 2016-02-12 | 2022-01-04 | The University Of Chicago | Compositions and methods related to antibodies that neutralize coagulase activity during Staphylococcus aureus disease |
BR112019026192B1 (pt) | 2017-06-10 | 2022-05-10 | Inventprise, Llc | Vacinas de conjugado multivalente com polissacarídeos de conjugado bivalente ou multivalente que fornecem imunogenicidade e avidez melhoradas |
US10729763B2 (en) | 2017-06-10 | 2020-08-04 | Inventprise, Llc | Mixtures of polysaccharide-protein pegylated compounds |
KR20200123436A (ko) | 2018-02-12 | 2020-10-29 | 이니뮨 코퍼레이션 | 톨-유사 수용체 리간드 |
US11103567B2 (en) * | 2018-12-06 | 2021-08-31 | Academia Sinica | Glycoconjugate vaccines, preparation method and uses thereof |
IL302449A (en) | 2020-11-04 | 2023-06-01 | Eligo Bioscience | CUTIBACTERIUM ACNES PHAGES RECOMBINANT, the production method and their uses |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003053462A2 (en) * | 2001-12-11 | 2003-07-03 | Merck & Co., Inc. | Staphylococcus aureus exopolysaccharide and process |
WO2004043405A2 (en) * | 2002-11-12 | 2004-05-27 | The Brigham And Women's Hospital, Inc. | Polysaccharide vaccine for staphylococcal infections |
WO2005016973A1 (en) * | 2003-08-12 | 2005-02-24 | Lipoxen Technologies Limited | Polysialic acid derivatives |
JP5491853B2 (ja) | 2006-03-30 | 2014-05-14 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | 免疫原性組成物 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4902506A (en) * | 1983-07-05 | 1990-02-20 | The University Of Rochester | Immunogenic conjugates |
AU2004220590B2 (en) | 2003-03-07 | 2010-02-18 | Inhibitex, Inc. | Polysaccharide - Staphylococcal surface adhesin carrier protein conjugates for immunization against nosocomial infections |
GB0426394D0 (en) * | 2004-12-01 | 2005-01-05 | Health Prot Agency | Fusion proteins |
-
2007
- 2007-03-28 AR ARP070101307A patent/AR060188A1/es active IP Right Grant
- 2007-03-28 AR ARP070101306A patent/AR060187A1/es active IP Right Grant
- 2007-03-29 JP JP2009502101A patent/JP5491853B2/ja active Active
- 2007-03-29 US US12/294,643 patent/US8933218B2/en active Active
- 2007-03-29 ES ES07727532.9T patent/ES2659050T3/es active Active
- 2007-03-29 WO PCT/EP2007/053059 patent/WO2007113223A2/en active Application Filing
- 2007-03-29 EP EP07727532.9A patent/EP2026841B1/en active Active
- 2007-03-29 US US12/294,689 patent/US8703148B2/en active Active
- 2007-03-29 ES ES07727531.1T patent/ES2659925T3/es active Active
- 2007-03-29 JP JP2009502102A patent/JP5759671B2/ja active Active
- 2007-03-29 EP EP07727531.1A patent/EP2019689B1/en active Active
- 2007-03-29 CA CA2647450A patent/CA2647450C/en active Active
- 2007-03-29 WO PCT/EP2007/053060 patent/WO2007113224A2/en active Application Filing
- 2007-03-29 CA CA2647455A patent/CA2647455C/en active Active
- 2007-03-30 TW TW096111419A patent/TWI425951B/zh active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003053462A2 (en) * | 2001-12-11 | 2003-07-03 | Merck & Co., Inc. | Staphylococcus aureus exopolysaccharide and process |
WO2004043405A2 (en) * | 2002-11-12 | 2004-05-27 | The Brigham And Women's Hospital, Inc. | Polysaccharide vaccine for staphylococcal infections |
WO2005016973A1 (en) * | 2003-08-12 | 2005-02-24 | Lipoxen Technologies Limited | Polysialic acid derivatives |
JP5491853B2 (ja) | 2006-03-30 | 2014-05-14 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | 免疫原性組成物 |
Non-Patent Citations (1)
Title |
---|
JPN5009002879; G.T.HENDERSON: BIOCONJUGATE TECHNIQUES , 1996, P3-136,187-188,218-200,228-248, ACADEMIC PRESS * |
Also Published As
Publication number | Publication date |
---|---|
EP2019689B1 (en) | 2018-01-10 |
AR060187A1 (es) | 2008-05-28 |
CA2647450A1 (en) | 2007-10-11 |
CA2647450C (en) | 2014-08-12 |
ES2659925T3 (es) | 2018-03-20 |
CA2647455C (en) | 2014-07-15 |
AR060188A1 (es) | 2008-05-28 |
US8703148B2 (en) | 2014-04-22 |
JP5491853B2 (ja) | 2014-05-14 |
JP5759671B2 (ja) | 2015-08-05 |
WO2007113224A2 (en) | 2007-10-11 |
EP2026841B1 (en) | 2017-12-27 |
WO2007113223A3 (en) | 2008-08-28 |
JP2009531388A (ja) | 2009-09-03 |
WO2007113223A2 (en) | 2007-10-11 |
US8933218B2 (en) | 2015-01-13 |
TW200815028A (en) | 2008-04-01 |
WO2007113224A3 (en) | 2008-06-05 |
CA2647455A1 (en) | 2007-10-11 |
TWI425951B (zh) | 2014-02-11 |
US20100303852A1 (en) | 2010-12-02 |
EP2026841A2 (en) | 2009-02-25 |
EP2019689A2 (en) | 2009-02-04 |
ES2659050T3 (es) | 2018-03-13 |
US20100322959A1 (en) | 2010-12-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5759671B2 (ja) | 結合方法 | |
US20180104323A1 (en) | Immunogenic composition | |
JP5683815B2 (ja) | ワクチンの製造方法 | |
JP2008513409A (ja) | 免疫原性組成物 | |
JP6773830B2 (ja) | 治療において使用するための免疫原性組成物 | |
JP6091214B2 (ja) | ポリ−グリセロールリン酸をベースにした抗グラム陽性細菌ワクチン | |
KR20010034124A (ko) | 포유동물에서 모락셀라(브란하멜라) 카타르할리스 감염의예방을 위한 리포올리고당에 기초한 백신 | |
TWI494124B (zh) | 免疫原組合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20100311 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20120802 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120807 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20121106 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20121204 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130401 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20130606 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20130809 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20140512 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20140515 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20150129 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150427 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20150608 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5759671 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |